Rituximab in systemic autoimmune rheumatic diseases: indications and practical use

ABSTRACT Objectives: To review the therapeutic option of Rituximab, a chimeric anti-CD20 antibody, in systemic autoimmune rheumatic diseases (SARDs) such as systemic lupus erythematosus, systemic sclerosis, primary Sjögren syndrome and idiopathic inflammatory myopathy. Methods: A non-systematic review was conducted. Results: The specific role and indication of rituximab in SARDs has been the subject of multiple trials in recent years. Evidence supports the use of rituximab in moderate-to-severe refractory systemic lupus erythematosus, diffuse skin involvement in systemic sclerosis and systemic involvement in primary Sjögren syndrome. Several guidelines have adopted these indications. In addition, there is a consensus about the use of rituximab in refractory myositis. The role of rituximab in interstitial lung disease associated with these SARDs needs to be further explored. Conclusion: Rituximab is a treatment option in several SARDs. Upcoming trials, use in daily practice and the safety profile are elaborated on.

• Publication year

  2018

• Venue

  Acta Clinica Belgica

• Publication date

  2018-09-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/17843286.2018.1521904PMID 30253707
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Update on Sjögren’s Syndrome 2018

  2018cited by this paper
• Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review.

  2018cited by this paper
• The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults

  2018influential reference
• Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis

  2018cited by this paper
• Primary Sjögren's Syndrome

  2018cited by this paper
• Rituximab in the treatment of inflammatory myopathies: a review.

  2017cited by this paper
• Treatment Guidelines for Rheumatologic Manifestations of Sjögren's Syndrome: Use of Biologic Agents, Management of Fatigue, and Inflammatory Musculoskeletal Pain

  2017cited by this paper
• Editorial: A New Classification of Adult Autoimmune Myositis

  2017cited by this paper
• The British Society for Rheumatology guideline for the management of adults with primary Sjögren’s Syndrome

  2017cited by this paper
• Rituximab in early systemic sclerosis

  2017cited by this paper
• Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab

  2017cited by this paper
• Randomized Controlled Trial of Rituximab and Cost‐Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome

  2017cited by this paper
• A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.

  2017cited by this paper
• The value of rituximab treatment in primary Sjögren's syndrome.

  2017cited by this paper
• Effects of rituximab in connective tissue disorders related interstitial lung disease.

  2016cited by this paper
• Systemic sclerosis: New evidence re-enforces the role of B cells.

  2016cited by this paper
• Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center.

  2016cited by this paper
• Beyond pan-B-cell-directed therapy — new avenues and insights into the pathogenesis of SLE

  2016cited by this paper
• BSR and BHPR guideline for the treatment of systemic sclerosis.

  2016cited by this paper
• Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised controlled trial

  2016cited by this paper
• Sjögren syndrome

  2016cited by this paper
• BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids.

  2016cited by this paper
• Update of EULAR recommendations for the treatment of systemic sclerosis

  2015cited by this paper
• Inflammatory muscle diseases.

  2015cited by this paper
• Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases.

  2015cited by this paper
• Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.

  2015cited by this paper
• Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.

  2015cited by this paper
• Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.

  2014influential reference
• Rituximab for Non‐Hodgkin's Lymphoma: A Story of Rapid Success in Translation

  2014cited by this paper
• Treatment of Primary Sjgren Syndrome With Rituximab

  2014cited by this paper
• Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases Results of a lower dosage and shorter interval regimen

  2014cited by this paper
• Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy.

  2014cited by this paper
• Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group

  2014cited by this paper
• Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.

  2014cited by this paper
• The Seductress

  2014cited by this paper
• Predictors of Clinical Improvement in Rituximab‐Treated Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis

  2014cited by this paper
• Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review.

  2014cited by this paper
• Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.

  2013influential reference
• Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis

  2013cited by this paper
• Two-year Results of an Open Pilot Study of a 2-treatment Course with Rituximab in Patients with Early Systemic Sclerosis with Diffuse Skin Involvement

  2013cited by this paper
• Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study

  2013cited by this paper
• Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections.

  2013cited by this paper
• EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial

  2013cited by this paper
• Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry

  2012cited by this paper
• Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis

  2012cited by this paper
• Rituximab in central nervous system manifestations of patients with primary Sjögren's syndrome: results from the AIR registry.

  2012cited by this paper
• Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome.

  2012cited by this paper
• American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis

  2012cited by this paper
• Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis.

  2012cited by this paper
• Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.

  2012cited by this paper
• Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis.

  2011cited by this paper
• Progressive multifocal leukoencephalopathy in refractory polymyositis treated with rituximab.

  2011cited by this paper
• Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER)

  2011cited by this paper
• Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.

  2010cited by this paper
• Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.

  2010cited by this paper
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

  2010cited by this paper
• Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

  2010cited by this paper
• EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

  2010cited by this paper
• Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab.

  2010cited by this paper
• B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial

  2010cited by this paper
• CD20 deficiency in humans results in impaired T cell-independent antibody responses.

  2010cited by this paper
• Rituximab: mechanism of action.

  2010cited by this paper
• B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis.

  2009cited by this paper
• Scleroderma.

  2009cited by this paper
• Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study

  2009cited by this paper
• WITHDRAWN: Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis.

  2009cited by this paper
• Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study

  2008cited by this paper
• Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study

  2008cited by this paper
• Orphanet Journal of Rare Diseases BioMed Central Review

  2006cited by this paper
• Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis.

  2005cited by this paper

• Rituximab and Intravenous Immunoglobulin (IVIG) for Refractory Eosinophilic Fasciitis: A Case Report

  2026cites this paper
• Autoimmune disease-associated lymphomas: research progress and review

  2026cites this paper
• Risk Factors for Infusion Reactions Associated With Rituximab Therapy

  2025cites this paper
• Analysis of risk factors for lethal outcome in patients of pediatric intensive care units with immuno-inflammatory diseases

  2025cites this paper
• British Society of Gastroenterology guidelines for diagnosis and management of autoimmune hepatitis

  2025cites this paper
• Human B-lymphopoiesis: Clinical challenges in B cell reconstitution and advances in in vitro modeling.

  2025cites this paper
• Considerations for Coronavirus Disease 2019 Vaccination Among B-Cell-Depleted Patients.

  2024cites this paper
• Can quantitative monitoring of B cells evaluate the efficacy of Rituximab in primary CNS demyelinating disorders?

  2024cites this paper
• The interplay between rheumatic diseases and pulmonary health

  2024cites this paper
• Switching from rituximab originator to GP2013 or CT-P10 biosimilars in autoimmune rheumatic diseases: drug retention rate and safety data from a multicentric retrospective cohort

  2024cites this paper
• The long‐term risk of immune‐related conditions in survivors of diffuse large B‐cell lymphoma: A Danish nationwide registry study

  2024cites this paper
• Interchangeability and adverse events in originator-rituximab and its biosimilar (CT-P10) among rheumatic patients: a real-life experience

  2023cites this paper
• The full range of ophthalmological clinical manifestations in systemic lupus erythematosus

  2023cites this paper
• Editorial: Autoimmune pre-disease

  2023cites this paper
• Rituximab and COVID-19 Infection in Patients with Autoimmune Rheumatic Diseases - A Real-World Study from India

  2023cites this paper
• Rituximab bij auto-immune blaarziekten

  2023cites this paper
• Therapeutic approach to the lung-kidney syndrome associated with systemic lupus erythematosus, a medical emergency that is a challenge for the clinician

  2023cites this paper
• The Underappreciated Role of Secretory IgA in IBD.

  2023cites this paper
• The impact of Rituximab administered before transplantation in patients undergoing allogeneic hematopoietic stem cell transplantation: A real-world study

  2022cites this paper
• Emerging Therapeutics in the Management of Connective Tissue Disease. Part I. Lupus Erythematosus and Sjögren's Syndrome.

  2022cites this paper
• Treatment with Rituximab in Rheumatoid Pneumoconiosis: A Case Report.

  2022cites this paper
• Treatment of persistent COVID-19 in two B-cell-depleted patients with the monoclonal antibody Sotrovimab

  2022cites this paper
• Long-term exposure to fine particulate matter and ozone and the onset of systemic autoimmune rheumatic diseases: an open cohort study in Quebec, Canada

  2022cites this paper
• Methotrexate induced neurotoxicity in a patient with rheumatoid arthritis on rituximab therapy: a case-based review

  2022cites this paper
• Rituximab therapy after pediatric hematopoietic stem cell transplantation can cause prolonged B-cell impairment and increases the risk for infections - a retrospective matched cohort study

  2022influential citation
• Subcutaneous immunoglobulin therapy for refractory skin thickening in rapidly progressive systemic sclerosis: A case report and literature review

  2022cites this paper
• Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease

  2021cites this paper
• Preparation and In Vitro Evaluation of RITUXfab-Decorated Lipoplexes to Improve Delivery of siRNA Targeting C1858T PTPN22 Variant in B Lymphocytes

  2021influential citation
• CMAR_A_339282 9319..9328

  2021cites this paper
• Use of Skin Testing Screening and Desensitization Before the First Exposure of Rituximab

  2021cites this paper
• Biomarkers of B cell activation in autoimmune connective tissue diseases: more than markers of disease activity.

  2021cites this paper
• The Safety of Medications During Pregnancy and Lactation in Patients with Inflammatory Rheumatic Diseases

  2021cites this paper
• Abordaje terapéutico del síndrome pulmón-riñón asociado con lupus eritematoso sistémico, una urgencia médica que es un reto para el clínico

  2021cites this paper
• Therapeutic potential of chimeric antigen receptor based therapies in autoimmune diseases.

  2021cites this paper
• Rituximab induced acute thrombocytopenia in a patient with systemic lupus erythematosus: a case report

  2021cites this paper
• A Phase-2 NIH-sponsored Randomized Clinical Trial of Rituximab in Scleroderma-associated Pulmonary Arterial Hypertension Did Not Reach Significance for Its Endpoints: End of Story? Not So Fast!

  2021cites this paper
• Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis

  2021influential citation
• Immunosuppressive Treatment in Antiphospholipid Syndrome: Is It Worth It?

  2021cites this paper
• Antigen presentation, autoantibody production, and therapeutic targets in autoimmune liver disease

  2020cites this paper
• Autoantibodies in idiopathic inflammatory myopathies: Clinical associations and laboratory evaluation by mono- and multispecific immunoassays.

  2019cites this paper
• Can We Expect Any Effect of Rituximab on Fatigue in Primary Sjögren Syndrome?

  2019cites this paper
• Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies

  2019cites this paper
• Update on Sjögren’s Syndrome 2018

  2018cites this paper
• World Journal of Critical Care Medicine

  year unknowncites this paper